Skip to main
MBX

MBX Stock Forecast & Price Target

MBX Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 11%

Bulls say

MBX Biosciences Inc. has demonstrated a significant clinical advancement with canvuparatide, highlighted by a 63% composite response at 12 weeks and a 69% response in both the 600 ug and 800 ug dosage groups, which surpassed expectations from both analysts and Key Opinion Leaders (KOLs). Additionally, strong patient engagement is evident, with 94% of subjects entering the open-label extension phase, signaling considerable enthusiasm and the potential for improved long-term efficacy. Furthermore, the promising safety profile of canvuparatide is underscored by minimal adverse events, along with supportive market research indicating a positive outlook for the drug's commercial viability in addressing endocrine disorders.

Bears say

MBX Biosciences Inc. faces significant downside risks that could negatively impact its financial performance and stock outlook. Specifically, there are concerns regarding the efficacy and safety outcomes of their Phase 2 and Phase 3 clinical trials for chronic hypoparathyroidism, coupled with the potential for unforeseen delays in research and development activities. Additionally, the company may encounter competitive pressures from new market entrants and existing therapies that outperform its product candidates, further exacerbating its financial challenges.

MBX has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 11% predict a Strong Sell.

This aggregate rating is based on analysts' research of MBX Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About MBX Biosciences Inc (MBX) Forecast

Analysts have given MBX a Buy based on their latest research and market trends.

According to 9 analysts, MBX has a Buy consensus rating as of Jan 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $51.67, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $51.67, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

MBX Biosciences Inc (MBX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.